Mantra Growth, page-38

I always assume that's traders realising no 10% bump is going to happen so exiting.
Seems to happen a lot if the stock doesn't take off on open. Could be wrong thou.

UBS was "1H17 result in-line with UBSe at the EBITDA & EPS level. Holding FY17 guidance is a
positive given uncertainty around the performance in the CBD segment, although
questions remain around organic growth given a large contribution from acquisitions."
Sort of "meh". They previously had a 3.40 target so not as bullish as a lot of other analysts.